Lv1
40 积分 2024-01-21 加入
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
10小时前
待确认
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
5天前
已完结
Trends in innovative drug development in China
15天前
已完结
Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma
17天前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
22天前
已完结
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
30天前
已完结
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
1个月前
已完结
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
1个月前
已完结
Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT
1个月前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
1个月前
已完结
皖公网安备34019202002308
